In partnership with
Education only. Not investment or medical advice.
Welcome Back, Longevity Investors.
Today, three longevity companies scored on both returns: the healthy years they could add and the business behind them. A therapy designed to make old cells young was tried in people for the first time. Ozempic's maker is now measuring aging inside its own trials. And an anti-inflammation pill from a company with cash into 2029 cut a heart-risk marker 85%. Let's dive in!
In today's issue:
The First Human Test Of Making Old Cells Young Again
Ozempic's Maker Is Now Measuring Aging In Its Own Trials
An Inflammation Pill Cut A Heart-Risk Marker 85%
Plus: an investor tip, quick hits, dated milestones and money moves
Read time: 5 minutes
Longevity Biotechs On The Move
🚨 FIRST IN HUMANS
The First Human Test Of Making Old Cells Young Again
Source: X / @lifebiosciences, Oct 8, 2026
EverLife: Could it add healthy years? Life Biosciences' ER-100 tries to roll aging cells back to a younger state, a bit like restoring a phone's software without erasing its data. Is the business strong? It's among the first companies to test this approach in people, and its first 3 patients tolerated it well.
Key Points:
No serious side effects through day 56
2 of 3 glaucoma patients had better vision-field test scores (early, with no comparison group)
Safety board recommended a 3x higher dose
Details: One eye injection delivers three reprogramming genes, switched on by an oral antibiotic for 56 days. Small and open-label, with no comparison group.
Dual ROI
🩺 Health: reprogramming has reversed signs of aging in animals for years. If it proves safe in people, it could later be tried in other tissues. Today it's 3 patients with one eye disease.
📈 Investors: Life Biosciences is private, co-founded by David Sinclair. As the first human test of reprogramming, its safety results set the bar for every company working on the same approach, including NewLimit and Retro.
SPONSORED BY SHORTFORM
The Book You Keep Meaning to Read Is Here
Everyone has a list of books they swear they'll get to. Atomic Habits. Never Split the Difference. The 48 Laws of Power.
Shortform has covered over 15,000 books, so the one you're thinking of is probably there. Each guide gives you the key ideas, how they connect to other books, and what to do with them.
Swap 10 minutes of scrolling for one big idea a day.
💊 BIG PHARMA
Ozempic's Maker Is Now Measuring Aging In Its Own Trials
Source: X / @biogerontology; Novo Nordisk preprint, Sept 22, 2026
EverLife: Could it add healthy years? In five trials with 10,052 people, blood-protein "aging clocks" ran younger on semaglutide than on placebo. Is the business strong? Novo Nordisk is one of the world's biggest drugmakers, and it's building aging data into a drug it already sells.
Key Points:
Heart biological age: about 2 to 4 years lower than placebo
Kidney, brain and lung clocks: about 1 to 4 years lower
Not fully explained by weight loss
Details: Most authors work at Novo Nordisk. The preprint isn't peer reviewed yet, and the authors say it doesn't prove rejuvenation.
Dual ROI
🩺 Health: already approved for diabetes, weight and heart risk. This hints at wider effects but doesn't prove it slows aging.
📈 Investors: Novo Nordisk (NYSE: NVO) is a public company readers can follow. If regulators ever accept aging as a treatable target, a drugmaker with this data inside approved products would start ahead. For now, regulators don't accept aging clocks as proof of benefit.
🔥 INFLAMMATION
An Inflammation Pill Cut A Heart-Risk Marker 85%
Source: Monte Rosa Therapeutics, Oct 1 and Aug 6, 2026
EverLife: Could it add healthy years? Monte Rosa's daily pill MRT-8102 shuts down NLRP3, a switch that drives the low-grade inflammation that rises with age and is tied to heart disease. Is the business strong? It has cash into 2029 and a big-pharma partner.
Key Points:
108 people with obesity and high heart risk, 4 weeks of dosing
hsCRP, a heart-risk blood marker, fell by a median 85%; IL-6 fell 54%
No serious side effects, and no sign of more infections
Details: Side effects were similar to placebo (33% vs 30%). Next: a Phase 2 in gout around year-end and a Phase 2b in coronary artery disease expected in the first half of 2027.
Dual ROI
🩺 Health: Chronic low-grade inflammation is one of the most consistent drivers of age-related disease. Lower hsCRP isn't yet proof of fewer heart attacks; that takes larger, longer trials.
📈 Investors: Monte Rosa (NASDAQ: GLUE) reported $626.0M in cash and securities on June 30, which it says lasts into 2029. It also has a Novartis deal worth up to $2.1B in milestones on a separate drug. BioAge (NASDAQ: BIOA) is chasing the same pathway.
Investor Tip
Read the trial design before the headline.
Two results here come from small studies with no comparison group: Life Bio's 3 patients and Rubedo's 11. They can show a treatment looks safe so far, not that it caused the improvement. People sometimes improve from extra attention or chance.
Before trusting a result, check the release for three things: randomized, placebo-controlled, and how many people. Missing any? Treat it as an early signal, not proof.
Quick Hits
🏛️ FDA: officials said aging will feature in the agency's next science-priorities report, expected early in fiscal 2027. These are remarks, not new rules.
💉 Eli Lilly (NYSE: LLY): retatrutide produced up to 20.8% weight loss over 80 weeks in type 2 diabetes, versus 4.0% on placebo.
🐷 eGenesis (private): one patient with its gene-edited pig kidney has passed 9 months off dialysis.
🧴 Rubedo (private): its skin treatment for "zombie" cells lowered skin epigenetic age by about 2 years in 11 people, versus their own baseline.
⚠️ Reality check: an NAD+ booster didn't slow early Parkinson's in a 410-person trial; the treated group declined slightly more than placebo.
On The Calendar
Early fiscal 2027: FDA's updated science-priorities report, which officials said will include aging
Q1 2027: Eli Lilly (NYSE: LLY) plans to file retatrutide with the FDA
Q1 2027: eGenesis (private) expects to start its 33-patient pig-kidney trial
First half of 2027: Monte Rosa (NASDAQ: GLUE) expects to start its 6-month heart-disease trial
No date given: Life Biosciences' higher-dose patient group
No date given: peer review of Novo Nordisk's aging-clock preprint
Money Moves
🩸 HexemBio (private): Draper Associates led a round bringing total funding to $15.5M for a therapy to restore aged blood stem cells. First human trial targeted for 2027. (Longevity.Technology, Sept 15)
🧬 Remedium Bio (private): first close of a planned $10M Series A, led by Lifespan Vision Ventures with Eli Lilly, to move its gene therapy toward human studies. (Company release, Aug 10)
🧠 Alector (NASDAQ: ALEC): Genentech (Roche) agreed to pay $100M upfront and up to $1.17B in milestones for early-stage Parkinson's drug AL050. (Alector release, Oct 5)
You Pick The Next Story
What should I cover in a future issue?
- Reprogramming after Life Bio's first human data: which companies are furthest along, and how they're funded
- Pig organs, eGenesis vs. United Therapeutics (NASDAQ: UTHR): where each one's trials stand, and which is public
- Big pharma's aging bets: which public companies are testing drugs against aging, and when results are due
- Money moves: which longevity investors are writing the biggest checks, and into what
- Something else: tell me what on the next page
For Members
Members get my 25-gate Dual ROI scores on longevity companies and see which companies I'm researching most closely.
How was today's issue?
Know someone who wants more healthy years? Forward this. Got this from a friend? Join free here.
Eric
This newsletter is general and impersonal. Nothing in it is a recommendation to buy, sell or hold any security, or an offer to sell or a solicitation of an offer to buy any security, and it doesn't consider your circumstances. Company plans and dates are the companies' own statements, not my forecasts.
I hold no position in, and receive no pay from, any company named here. Monte Rosa is on the EverLife Scout list, an educational research list, not a recommendation. BioAge is on the EverLife Watch List. I hold personal equity in Repair Biotechnologies and Yuva Biosciences, neither discussed here. Treatments mentioned are experimental unless noted as approved. Full disclosure and terms.